OR WAIT null SECS
Lonza’s new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion.
Lonza announced on April 23, 2021 that it is launching a new small-molecule manufacturing complex at its Visp, Switzerland, site.
The new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion including drug substance and particle engineering technologies. such as spray drying dispersion, and drug product, Lonza said in a company press release.
“This collaboration is a great example of how we are supporting our customers with flexible business models,” said Gordon Bates, president and head of Small Molecules, Lonza, in the press release. “Our customers developing highly potent and increasingly complex medicines trust us to handle these toxic substances throughout their clinical and commercial lifecycle. The investment to realize this new manufacturing complex for small molecules creates a substantial footprint for accelerating future growth capacity across the range of our small-molecule service offering.”